Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) fell 1.7% on Tuesday . The company traded as low as $54.53 and last traded at $54.77. 10,144,526 shares were traded during trading, a decline of 16% from the average session volume of 12,065,267 shares. The stock had previously closed at $55.74.
Analyst Ratings Changes
A number of research firms recently issued reports on NVO. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. Berenberg Bank raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Wednesday, September 17th. HSBC set a $70.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, October 1st. Finally, Rothschild & Co Redburn raised Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research note on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $76.00.
Check Out Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Stock Down 1.7%
The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The stock has a market cap of $244.55 billion, a price-to-earnings ratio of 15.05, a price-to-earnings-growth ratio of 2.50 and a beta of 0.68. The firm has a 50 day simple moving average of $56.36 and a two-hundred day simple moving average of $62.64.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.
Novo Nordisk A/S Cuts Dividend
The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.
Hedge Funds Weigh In On Novo Nordisk A/S
Several hedge funds have recently made changes to their positions in the business. First Hawaiian Bank grew its position in Novo Nordisk A/S by 0.6% in the first quarter. First Hawaiian Bank now owns 22,401 shares of the company's stock valued at $1,556,000 after purchasing an additional 142 shares in the last quarter. Anchor Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 1.1% in the 1st quarter. Anchor Investment Management LLC now owns 13,597 shares of the company's stock valued at $944,000 after acquiring an additional 150 shares in the last quarter. Xponance Inc. increased its position in shares of Novo Nordisk A/S by 5.0% in the first quarter. Xponance Inc. now owns 3,314 shares of the company's stock valued at $230,000 after acquiring an additional 158 shares during the last quarter. Foster Dykema Cabot & Partners LLC boosted its position in Novo Nordisk A/S by 3.8% during the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company's stock valued at $319,000 after purchasing an additional 166 shares during the last quarter. Finally, Werba Rubin Papier Wealth Management grew its stake in Novo Nordisk A/S by 4.1% in the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company's stock valued at $302,000 after purchasing an additional 173 shares in the last quarter. 11.54% of the stock is owned by institutional investors.
Novo Nordisk A/S Company Profile
(
Get Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.